TAMBO, INC.
San Francisco, CA · Biotech · Private
Click Activated Protodrugs (CAP) platform—a biopolymer-based drug activation system using bioorthogonal click chemistry to selectively activate modified drugs at specific body sites
shasqi.com →- Grants
- $6.5M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 3 granted · 37 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Biomaterials and Chemistry to Enhance the Delivery of Medicines in the Body | $179,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Using implantable biomaterial and bio-orthogonal chemistry to guide delivery of antibiotics | $224,984 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: Biomaterials and Chemistry to Enhance the Delivery of Medicines in the Body | $749,906 | |
| Federal grant | Department of Health and Human Services · Phase I · Material guided drug delivery for pediatric tumors using an implantable biomaterial and bio-orthogonal chemistry | $299,877 | |
| Federal grant | Department of Health and Human Services · Phase I · Material guided drug delivery for pigmented villonodular synovitis using an implantable biomaterial and bio-orthogonal chemistry | $295,394 | |
| Federal grant | Department of Health and Human Services · Phase II · Material-guided delivery and local activation of bioorthogonal prodrugs | $216,910 | |
| Federal grant | Department of Health and Human Services · Phase II · Material-guided delivery and local activation of bioorthogonal prodrugs | $1,488,608 | |
| Federal grant | Department of Health and Human Services · Phase II · Material-guided delivery and local activation of bioorthogonal prodrugs | $577,898 | |
| Federal grant | Department of Health and Human Services · Phase I · Generalizable Protodrug Characteristics for In Vivo Drug Release using the Click Activated Protodrugs (CAP) Platform | $300,224 | |
| Federal grant | Department of Health and Human Services · Phase II · Discovery of solubilizing side chains for in vivo release of diverse drug classes using the Click Activated Protodrugs (CAP) platform | $929,651 | |
| Federal grant | Department of Health and Human Services · Phase II · Discovery of solubilizing side chains for in vivo release of diverse drug classes using the Click Activated Protodrugs (CAP) platform | $1,209,827 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2811 | Ensoma | — | $120M |
| 2812 | A2 Biotherapeutics | — | $119M |
| 2813 | Interius BioTherapeutics | — | $118M |
| 2814 | TAMBO, INC. | — | — |
| 2815 | Diapin Therapeutics LLC | — | — |
| 2816 | Mineralys Therapeutics, Inc. | — | $118M |
| 2817 | LYST THERAPEUTICS LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Trans-Cyclooctene Prodrug of Monomethyl Auristatin Egranted
- Bioorthogonal Compositionsgranted
- Trans-cyclooctene Bioorthogonal Agents And Uses In Cancer And Immunotherapyapplication
- Tetrazine Conjugates For In Vivo Targeted Delivery Of A Payloadapplication
- Bioorthogonal Compositionsapplication
- Trans-cyclooctene-modified Bispecific Antibodiesapplication
- Trans-cyclooctene Bioorthogonal Agents And Uses In Cancer And Immunotherapyapplication
- Bioorthogonal Compositionsapplication
- Bioorthogonal Compositionsgranted
- Tetrazine-based Targeting Agents For In Vivo Delivery Of A Payloadapplication
- Trans-cyclooctene Conjugatesapplication
- Trans-cyclooctene Conjugatesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.